San Francisco, USA and Suzhou, China September 28, 2020 / PRNewswire-Asianet /-INNOVENT BIO Pharmaceutical (Hong Kong Stock Exchange: 01801), a biopharmaceutical company dedicated to the research, development, production and sale of innovative drugs for the treatment of tumors, metabolic diseases, autoimmunity and other major diseases, announced that it will hold an online R & D day on November 10, focusing on the company's R & D pipeline and R & D direction. The event will be held from 8am to 12:00 Beijing time on November 10th and from 9pm to 1am Beijing time (+ 1 day) in English. The agenda and registration information of the meeting are as follows.
Number of Chinese shows*
Tuesday, November 10, 2020
8 a.m. to 12:00 China / Singapore
English performance*
Tuesday, November 10, 2020
9: 00 p.m. to 1: 00 a.m. (+ 1 day) China / Singapore
8 a.m. to 12:00 United States (Eastern time)
1: 00 p.m. to 5: 00 p.m. UK (London time)
Chinese session agenda(China time)
Development and Prospect of INNOVENT BIO Pharmaceutical from 8 a.m. to 08:30
Keynote speeches and in-depth exchanges in the R & D section from 08:30 to 11:00
11:00 to 12:00 Round Table Forum: comprehensive discussion
Main management
Founder, Chairman and Chief Executive Officer of Dr. Yu Dechao
Mr. Xi Hao, Chief Financial Officer, Executive Director
Mr. Liu Min, Chief Commercial Officer
Key members of the R & D / clinical / commercial / CMC/BD team
Moderator: Ms. Zhu Xiaoxiao, Senior Director of Investor Relations
Meeting registration information
1. Entry for registration in Chinese:
two。 Entry for registration of English events:
3. Investors and analysts attending the meeting must pre-register through the link above. The registration port is open. Please complete the registration before November 8.
4. After the registration is approved, you will receive an email notification with an active link and login password. You will attend the meeting with this login password, please keep it safe.
5. If you have any questions during the registration process, please contact
* this event is divided into Chinese and English sessions. The contents and agenda of the two meetings are the same. Please select the corresponding sessions to sign up for the event.
About INNOVENT BIO
It is INNOVENT BIO's ideal and goal to develop high-quality biopharmaceuticals that are affordable to ordinary people. Founded in 2011, INNOVENT BIO is committed to the development, production and sale of innovative drugs for the treatment of tumors, metabolic diseases, autoimmunity and other major diseases. INNOVENT BIO Pharmaceutical was listed on the main board of the Stock Exchange of Hong Kong Limited on October 31, 2018, stock code: 01801.
Since its establishment, the company has stood out among many biopharmaceutical companies by virtue of its innovative achievements and international operation model. A product chain consisting of 23 new drug varieties has been established, covering many disease areas such as oncology, metabolic diseases and autoimmunity, among which 6 varieties have been selected into the national "major new drug creation" project, and 3 products (Xindirizumab injection, trade name: Dabeshu)®, English trademark: TYVYT®Bevacizumab injection, trade name: Dayutong®, English trademark: BYVASDA®Adamumab injection, trade name: Su Lixin®, English trademark: SULINNO®Approved by NMPA for sale, one application for marketing of McAbs was accepted by the State Drug Administration and included in the priority review. 4 varieties have entered the III phase or key clinical studies, and another 15 products have entered or are about to enter clinical studies. Cindilizumab successfully entered the national health insurance catalogue in November 2019, becoming the only PD-1 inhibitor to enter the new national health insurance catalogue.
INNOVENT BIO has set up a high-end biopharmaceutical development and industrialization talent team with international advanced level, and has reached strategic cooperation with excellent international enterprises such as Eli Lilly and Co Pharmaceutical, Adimab, Incyte, MD Anderson Cancer Center, Alector and Hanmi in South Korea. For more information, please visit the company's website.